Note: Originally published on Nov. 12, 2025, this resource is updated as needed, most recently on August 12, 2026, to reflect the latest policy shifts and legal developments.
Since the commencement of his second term in January 2025, President Donald Trump has initiated a sweeping overhaul of the U.S. public health apparatus. Through the Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy, Jr., the administration has prioritized the "Make America Healthy Again" (MAHA) agenda. This strategy has resulted in significant structural reorganization, the removal of long-standing federal guidance, and a pivot in how the government approaches chronic disease, infectious disease, and administrative oversight.
This report summarizes key administrative actions in chronological order and analyzes their broader implications for the American public health landscape.
The MAHA Agenda: Structural and Procedural Shifts
The administration’s public health philosophy is rooted in the belief that federal agencies require a fundamental shift in focus—away from what they term "overmedicalization" and toward addressing the root causes of chronic disease, such as nutrition, environmental toxins, and lifestyle factors.
Key Chronological Developments
- January 20, 2025: President Trump issues Executive Orders (EOs) revoking several Biden-era policies regarding diversity, equity, and inclusion (DEI) and "gender ideology." These EOs prompted the removal of thousands of federal websites and databases, specifically those related to health disparities, HIV/AIDS, and LGBTQ+ health. Following public outcry and litigation, the administration agreed in September 2025 to restore these sites to their January 2025 versions.
- February 13, 2025: Robert F. Kennedy, Jr. is confirmed as HHS Secretary by a 52-48 Senate vote. On the same day, President Trump establishes the MAHA Commission, charging it with developing a 180-day strategy to combat childhood chronic disease.
- February 28, 2025: Secretary Kennedy rescinds the "Richardson Waiver," effectively ending the requirement for public comment on HHS grants and contracts. This change, while intended to streamline bureaucratic processes, has drawn criticism for reducing transparency in how federal health funds are managed.
- March 27, 2025: HHS announces a massive restructuring, including a plan to eliminate 20,000 positions and create an "Administration for a Healthy America" (AHA). Despite a Supreme Court ruling in July 2025 that cleared the way for workforce reductions, the legislative formation of the AHA remains stalled in Congress.
- June 9, 2025: Secretary Kennedy dismisses all 17 sitting members of the Advisory Committee on Immunization Practices (ACIP), replacing them with new appointees who have frequently expressed skepticism toward established COVID-19 vaccine protocols.
- August 15, 2025: HHS reinstates the Task Force on Safer Childhood Vaccines, a move long championed by advocacy groups like Children’s Health Defense, to increase oversight of vaccine safety and adverse reporting.
Clinical and Regulatory Policy Overhauls
The administration’s approach to medical regulation has been characterized by a move toward stricter clinical trial requirements for vaccines, coupled with a push to accelerate drug approvals for rare diseases and "national priorities."
Vaccine Policy and Oversight
The most significant shifts have occurred within the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). In May 2025, the administration removed COVID-19 vaccines from the routine immunization schedule for healthy children and pregnant women, shifting to a "shared decision-making" model. This led to a cascade of lawsuits from professional medical organizations, such as the American Academy of Pediatrics (AAP), challenging the administration’s departure from established federal procedures.
The "National Priority" Voucher Program
In June 2025, the FDA introduced "National Priority Vouchers," which significantly shorten the regulatory review time for drugs deemed to serve the "U.S. national interest." While supporters argue this encourages domestic manufacturing, critics—including public health experts—warn that these vouchers may strain the agency’s already reduced staff capacity, potentially leading to bottlenecks in other critical drug reviews.
Supporting Data: Impacts on Funding and Personnel
The "reduction in force" (RIF) initiatives at HHS have had a quantifiable impact on agency operations. As of August 2025, the administration had met its goal of cutting 20,000 jobs.
- Public Health Funding: In March 2025, the administration attempted to claw back $11.4 billion in supplemental COVID-19 funding from state and local departments. While federal courts blocked this in several states, nearly 80% of the funds were restored only for the 23 states that joined the litigation, leaving a significant funding gap in others.
- Research Cuts: The cancellation of $500 million in mRNA vaccine research in August 2025 marked a definitive pivot away from the platform used to combat COVID-19. HHS officials stated the funding was being reallocated to platforms with "stronger safety records," though researchers have expressed concern that this will stifle innovation in cancer treatments and other infectious disease therapies.
Official Responses and Legal Battles
The administration’s policies have triggered an unprecedented volume of litigation.
- Judicial Intervention: Federal judges have played a pivotal role in curbing certain administrative actions. In April 2025, a permanent injunction was placed on the NIH’s plan to lower indirect cost rates for research grants. Similarly, in March 2026, a federal judge stayed the implementation of the revised childhood immunization schedule, citing a failure to follow the Administrative Procedure Act.
- Agency Leadership Turnover: The tenure of CDC Director Susan Monarez, who served only 28 days before being removed in August 2025, highlighted the internal friction between the administration’s political goals and the career civil service. Monarez testified that her removal stemmed from her refusal to provide "blanket approval" for policy changes without rigorous review.
Broader Implications for Public Health
The cumulative effect of these actions is a profound decentralization and questioning of the traditional public health consensus.
The Erosion of Consensus
The most contentious development occurred in November 2025, when the CDC updated its website to state that a link between vaccines and autism "cannot be ruled out." This directly contradicts the long-standing scientific consensus held by the AMA, AAP, and global health bodies. This shift, along with the cancellation of the "Safe to Sleep" program and the limitation of bird flu (H5N1) tracking, has raised concerns among epidemiologists regarding the nation’s ability to monitor and respond to emerging health threats.
Impact on Preventive Services
The repeated cancellation of meetings for the U.S. Preventive Services Task Force (USPSTF) has effectively paralyzed federal guidance on preventive care. Because the Affordable Care Act (ACA) ties insurance coverage mandates to USPSTF recommendations, the lack of new guidance leaves a significant void in what services are guaranteed to be covered without cost-sharing.
A New Era of "Shared Decision-Making"
By moving numerous vaccines—including hepatitis B, influenza, and COVID-19—to a model of "shared clinical decision-making," the administration is shifting the responsibility of immunization strategy from federal health experts to individual physician-patient consultations. While the administration frames this as "restoring trust" and providing choice, professional organizations warn that this could lead to lower vaccination rates, increased health inequities, and administrative chaos for healthcare providers navigating coverage requirements.
Future Outlook
As of August 2026, the legal and administrative struggle over the direction of U.S. public health continues. With the administration’s most recent Executive Order in August 2026 again directing the realignment of childhood vaccine recommendations with "peer, developed countries," the focus remains on dismantling the existing structure to replace it with a model that prioritizes individual choice and alternative safety evaluation methods.
For the American public, these changes represent the most significant realignment of health policy in over a century. The tension between the administration’s drive for structural reform and the institutional resistance from the scientific and legal communities remains the defining characteristic of this period in American health policy.
Disclaimer: This report is a summary of administrative actions and is not exhaustive of all federal health policies. For further information on specific health topics, readers are encouraged to consult the official documentation provided by the relevant agencies and the ongoing dockets in federal court proceedings.
About the Author
